RxDoctor Payments Data

David Pohl, DO

Family Medicine · Lansing, MINPI 1023437274

Payments from drug & device makers

$7,120in general payments, 2019–2025

Across 435 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$989
  • Amgen$935
  • AbbVie$828
  • Pfizer$488
  • GSK$438
  • AstraZeneca$335
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$7,120100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,120 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$38,290
Medicare patients
101
Services billed
542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$102,573
EliquisApixaban79$89,389
FarxigaDapagliflozin Propanediol54$84,371
JardianceEmpagliflozin64$82,945
MounjaroTirzepatide75$79,466
TrulicityDulaglutide40$58,589
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$52,824
JanuviaSitagliptin Phosphate41$51,518
InvokanaCanagliflozin23$37,281
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog35$33,454
Tresiba Flextouch U-200Insulin Degludec18$32,538
XareltoRivaroxaban23$27,252
Breo ElliptaFluticasone/Vilanterol31$26,981
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$24,738
Janumet XrSitagliptin Phos/Metformin Hcl21$13,635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$302$138,055115 claims
AstraZenecaFarxiga, Breztri Aerosphere$335$109,10880 claims
Novo NordiskOzempic$989$102,57372 claims
PfizerEliquis, Premarin$488$96,00991 claims
Boehringer IngelheimJardiance$164$82,94564 claims
GSKTrelegy Ellipta, Breo Ellipta$438$79,80571 claims
MerckJanuvia, Janumet Xr$84$65,15362 claims
Johnson & JohnsonInvokana, Xarelto$31$64,53246 claims
Antares Pharma, Inc.Xyosted$155$11,91216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →